BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20466978)

  • 1. C-reactive protein and risk of venous thromboembolism in the general population.
    Zacho J; Tybjaerg-Hansen A; Nordestgaard BG
    Arterioscler Thromb Vasc Biol; 2010 Aug; 30(8):1672-8. PubMed ID: 20466978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population.
    Marott SC; Nordestgaard BG; Zacho J; Friberg J; Jensen GB; Tybjaerg-Hansen A; Benn M
    J Am Coll Cardiol; 2010 Aug; 56(10):789-95. PubMed ID: 20797493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive protein and the risk of cancer: a mendelian randomization study.
    Allin KH; Nordestgaard BG; Zacho J; Tybjaerg-Hansen A; Bojesen SE
    J Natl Cancer Inst; 2010 Feb; 102(3):202-6. PubMed ID: 20056955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism: A focus on fibrinogen, factor VIII, and high-sensitivity C-reactive protein (hs-CRP).
    Luxembourg B; Schmitt J; Humpich M; Glowatzki M; Dressler D; Seifried E; Lindhoff-Last E
    Thromb Haemost; 2009 Oct; 102(4):668-75. PubMed ID: 19806251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and biochemical markers of obstructive lung disease in the general population.
    Dahl M
    Clin Respir J; 2009 Apr; 3(2):121-2. PubMed ID: 20298391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study.
    Jeppesen J; Hansen TW; Olsen MH; Rasmussen S; Ibsen H; Torp-Pedersen C; Hildebrandt PR; Madsbad S
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):594-8. PubMed ID: 18753952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
    Nordestgaard BG; Zacho J
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study.
    Holst AG; Jensen G; Prescott E
    Circulation; 2010 May; 121(17):1896-903. PubMed ID: 20404252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-reactive protein as a predictor of hypertension in the Hong Kong Cardiovascular Risk Factor Prevalence Study (CRISPS) cohort.
    Cheung BM; Ong KL; Tso AW; Leung RY; Xu A; Cherny SS; Sham PC; Lam TH; Lam KS
    J Hum Hypertens; 2012 Feb; 26(2):108-16. PubMed ID: 21270838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study.
    Siemes C; Visser LE; Coebergh JW; Splinter TA; Witteman JC; Uitterlinden AG; Hofman A; Pols HA; Stricker BH
    J Clin Oncol; 2006 Nov; 24(33):5216-22. PubMed ID: 17114654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients.
    Roman RM; Camargo PV; Borges FK; Rossini AP; Polanczyk CA
    Coron Artery Dis; 2010 May; 21(3):129-36. PubMed ID: 20305551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
    Dosh K; Berger PB; Marso S; van Lente F; Brennan DM; Charnigo R; Topol EJ; Steinhubl S
    Circ Cardiovasc Interv; 2009 Dec; 2(6):503-12. PubMed ID: 20031767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of interleukin-6 and C-reactive protein genetic polymorphisms levels with venous thromboembolism.
    Mahemuti A; Abudureheman K; Aihemaiti X; Hu XM; Xia YN; Tang BP; Upur H
    Chin Med J (Engl); 2012 Nov; 125(22):3997-4002. PubMed ID: 23158132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.
    Ay C; Vormittag R; Dunkler D; Simanek R; Chiriac AL; Drach J; Quehenberger P; Wagner O; Zielinski C; Pabinger I
    J Clin Oncol; 2009 Sep; 27(25):4124-9. PubMed ID: 19636003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum lipoprotein (a) levels in patients with first unprovoked venous thromboembolism is not associated with subsequent risk of recurrent VTE.
    Rodger MA; Le Gal G; Carrier M; Betancourt MT; Kahn SR; Wells PS; Anderson DA; Lacut K; Chagnon I; Solymoss S; Crowther M; Perrier A; White R; Vickars L; Ramsay T; Kovacs MJ
    Thromb Res; 2010 Sep; 126(3):222-6. PubMed ID: 20580413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients.
    Goei D; Hoeks SE; Boersma E; Winkel TA; Dunkelgrun M; Flu WJ; Schouten O; Bax JJ; Poldermans D
    Coron Artery Dis; 2009 May; 20(3):219-24. PubMed ID: 19322079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy.
    de Maat MP; Madsen JS; Langdahl B; Bladbjerg EM; Tofteng CL; Abrahamsen B; Rejnmark L; Brixen K; Christensen K; Jespersen J; Kristensen SR
    Thromb Haemost; 2007 Feb; 97(2):234-9. PubMed ID: 17264952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembolism.
    Ay C; Jungbauer LV; Kaider A; Koder S; Panzer S; Pabinger I; Mannhalter C
    Thromb Haemost; 2008 May; 99(5):899-904. PubMed ID: 18449419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
    Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
    Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The VITA project: prothrombin G20210A mutation and venous thromboembolism in the general population.
    Tosetto A; Missiaglia E; Frezzato M; Rodeghiero F
    Thromb Haemost; 1999 Nov; 82(5):1395-8. PubMed ID: 10595625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.